MX376087B - Inhibidores macrocíclicos de cinasa rip2. - Google Patents

Inhibidores macrocíclicos de cinasa rip2.

Info

Publication number
MX376087B
MX376087B MX2017003469A MX2017003469A MX376087B MX 376087 B MX376087 B MX 376087B MX 2017003469 A MX2017003469 A MX 2017003469A MX 2017003469 A MX2017003469 A MX 2017003469A MX 376087 B MX376087 B MX 376087B
Authority
MX
Mexico
Prior art keywords
kinase inhibitors
macrocyclic
rip2 kinase
compounds
rip2
Prior art date
Application number
MX2017003469A
Other languages
English (en)
Spanish (es)
Other versions
MX2017003469A (es
Inventor
Jan Hoflack
Pascal Benderitter
Petra Blom
Original Assignee
Oncodesign Prec Medicine Opm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncodesign Prec Medicine Opm filed Critical Oncodesign Prec Medicine Opm
Publication of MX2017003469A publication Critical patent/MX2017003469A/es
Publication of MX376087B publication Critical patent/MX376087B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2017003469A 2014-09-17 2015-09-17 Inhibidores macrocíclicos de cinasa rip2. MX376087B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14185130 2014-09-17
PCT/EP2015/071347 WO2016042087A1 (en) 2014-09-17 2015-09-17 Macrocyclic rip2 kinase inhibitors

Publications (2)

Publication Number Publication Date
MX2017003469A MX2017003469A (es) 2017-05-08
MX376087B true MX376087B (es) 2025-03-07

Family

ID=51687776

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003469A MX376087B (es) 2014-09-17 2015-09-17 Inhibidores macrocíclicos de cinasa rip2.

Country Status (26)

Country Link
US (1) US10676486B2 (enExample)
EP (1) EP3194407B1 (enExample)
JP (1) JP6736545B2 (enExample)
KR (1) KR102563829B1 (enExample)
CN (1) CN106687464B (enExample)
AU (1) AU2015316799B2 (enExample)
BR (1) BR112017004035B1 (enExample)
CA (1) CA2958782C (enExample)
DK (1) DK3194407T3 (enExample)
EA (1) EA032872B1 (enExample)
ES (1) ES2763344T3 (enExample)
HR (1) HRP20192334T1 (enExample)
HU (1) HUE048518T2 (enExample)
IL (1) IL250544B (enExample)
LT (1) LT3194407T (enExample)
MX (1) MX376087B (enExample)
MY (1) MY186523A (enExample)
PL (1) PL3194407T3 (enExample)
PT (1) PT3194407T (enExample)
SA (1) SA517381087B1 (enExample)
SG (1) SG11201701116XA (enExample)
SI (1) SI3194407T1 (enExample)
TW (1) TWI709563B (enExample)
UA (1) UA121315C2 (enExample)
WO (1) WO2016042087A1 (enExample)
ZA (1) ZA201701331B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102719387B1 (ko) * 2017-01-26 2024-10-21 한미약품 주식회사 이미다조피리다진 화합물
AR124556A1 (es) 2020-01-31 2023-04-12 Oncodesign Sa Inhibidores macrocíclicos de rip2-cinasa
WO2024051631A1 (zh) * 2022-09-07 2024-03-14 苏州朗睿生物医药有限公司 一种大环咪唑并[1,2-b]哒嗪衍生物及其制备方法和用途
CN120500490A (zh) * 2023-01-03 2025-08-15 广东新契生物医药科技有限公司 作为usp1抑制剂的大环化合物
WO2025212514A2 (en) * 2024-04-02 2025-10-09 Interline Therapeutics, Inc. Methods of treating inflammatory diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
SK283569B6 (sk) 1993-10-01 2003-09-11 Astra Aktiebolag Spôsob spracovania jemne deleného práškového liečiva, zariadenie na vykonávanie tohto spôsobu a aglomeráty vyrobené týmto spôsobom
US6043358A (en) 1995-11-01 2000-03-28 Merck & Co., Inc. Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US7750007B2 (en) * 2006-11-06 2010-07-06 Supergen, Inc. Imidazo[1,2-beta]pyridazine and pyrazolo[1,5-alpha]pyrimidine derivatives and their use as protein kinase inhibitors
AR077468A1 (es) * 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
AU2011256380C1 (en) * 2010-05-20 2016-09-08 Array Biopharma Inc. Macrocyclic compounds as Trk kinase inhibitors
WO2013001310A1 (en) 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
TWI547494B (zh) * 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
ES2583477T3 (es) 2011-09-30 2016-09-21 Ipsen Pharma S.A.S. Inhibidores macrocíclicos de cinasa de LRRK2
KR20140078710A (ko) * 2011-09-30 2014-06-25 온코디자인 에스.에이. 거대고리 flt3 키나제 억제제

Also Published As

Publication number Publication date
LT3194407T (lt) 2020-01-27
DK3194407T3 (da) 2020-01-27
EP3194407A1 (en) 2017-07-26
AU2015316799B2 (en) 2019-07-11
TW201619168A (zh) 2016-06-01
TWI709563B (zh) 2020-11-11
BR112017004035A2 (pt) 2017-12-05
HUE048518T2 (hu) 2020-07-28
PT3194407T (pt) 2020-01-20
BR112017004035A8 (pt) 2023-05-09
CN106687464B (zh) 2020-03-03
CN106687464A (zh) 2017-05-17
JP6736545B2 (ja) 2020-08-05
PL3194407T3 (pl) 2020-04-30
CA2958782C (en) 2024-01-09
EA201790609A1 (ru) 2017-07-31
IL250544B (en) 2020-06-30
NZ730758A (en) 2023-09-29
WO2016042087A1 (en) 2016-03-24
JP2017528481A (ja) 2017-09-28
CA2958782A1 (en) 2016-03-24
IL250544A0 (en) 2017-03-30
EA032872B1 (ru) 2019-07-31
HRP20192334T1 (hr) 2020-03-20
US10676486B2 (en) 2020-06-09
KR102563829B1 (ko) 2023-08-03
KR20170048596A (ko) 2017-05-08
AU2015316799A1 (en) 2017-04-27
EP3194407B1 (en) 2019-10-23
UA121315C2 (uk) 2020-05-12
SI3194407T1 (sl) 2020-03-31
ZA201701331B (en) 2020-07-29
ES2763344T3 (es) 2020-05-28
SA517381087B1 (ar) 2021-02-09
MY186523A (en) 2021-07-24
MX2017003469A (es) 2017-05-08
BR112017004035B1 (pt) 2023-11-14
US20190127390A1 (en) 2019-05-02
SG11201701116XA (en) 2017-03-30

Similar Documents

Publication Publication Date Title
MX2015011359A (es) Inhibidores macrociclicos de cinasa 2 de repeticion rica en leucina (lrrk2).
MX2019001125A (es) Inhibidores de cinasa macrociclica.
PH12017501921A1 (en) Novel compounds
MX2015012526A (es) Inhibodores macrociclicos de cinasa rip2.
DOP2017000109A (es) Derivados de feniltriazol sustituido con hidroxialquilo y sus usos
MX2015012528A (es) Inhibidores macrociclicos de cinasa inducibles por sal.
EA201690159A1 (ru) Способы и композиции для лечения рака
PH12017500453B1 (en) Spirocyclic inhibitors of cathepsin c
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
MX373129B (es) Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas.
TR201904514T4 (tr) Makrosiklik LRRK2 kinaz inhibitörleri.
PH12016502353A1 (en) Pharmaceutical composition
PH12016502352A1 (en) Pharmaceutical composition
MX2019006863A (es) Inhibidores de heparanasa y uso de los mismos.
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
MX376087B (es) Inhibidores macrocíclicos de cinasa rip2.
BR112017004580A2 (pt) composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento.
EA201692020A1 (ru) Пролекарственные средства янтарной кислоты для применения в лечении лактоацидоза или индуцируемого лекарственными средствами побочного действия вследствие связанных с комплексом i нарушений окислительного фосфорилирования в митохондриях
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases

Legal Events

Date Code Title Description
FG Grant or registration